Develops drugs for neurological and psychiatric disorders.
Jun 2026Revenue $3.37B/yrExpenses $2.58B/yr
Reached break-even Oct 2018
Figures by year
When did Neurocrine Biosciences become profitable?
Its revenue passed its expenses in Oct 2018. In the 12 months to Jun 2026, revenue was $3.37B and expenses $2.58B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.86B | $2.24B | $619M |
| Dec 2024 | $2.36B | $1.78B | $571M |
| Dec 2023 | $1.89B | $1.64B | $251M |
| Dec 2022 | $1.49B | $1.24B | $249M |
| Dec 2021 | $1.13B | $1.03B | $103M |
| Dec 2020 | $1.05B | $883M | $163M |
| Dec 2019 | $788M | $716M | $72.3M |
| Dec 2018 | $451M | $414M | $36.8M |
| Dec 2017 | $162M | $293M | −$131M |
| Dec 2016 | $15.0M | $162M | −$147M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.